AmpliPhi BioSciences Corporation (APHB)

0.31
AMEX
Prev Close 0.32
Day Low/High 0.28 / 0.33
52 Wk Low/High 0.15 / 1.37
Exchange AMEX
Shares Outstanding 32.77B
Market Cap 10.41M
Div & Yield N.A. (N.A)
AmpliPhi Biosciences To Present At Biotech Showcase 2018

AmpliPhi Biosciences To Present At Biotech Showcase 2018

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Provides Corporate And Strategic Update

AmpliPhi Biosciences Provides Corporate And Strategic Update

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced its...

AmpliPhi Biosciences To Present At LD Micro 10th Annual Main Event

AmpliPhi Biosciences To Present At LD Micro 10th Annual Main Event

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Hold 2017 Third Quarter And Business Update Conference Call On November 14

AmpliPhi Biosciences To Hold 2017 Third Quarter And Business Update Conference Call On November 14

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Participate In The BIO-Europe 2017 Conference

AmpliPhi Biosciences To Participate In The BIO-Europe 2017 Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences To Participate In Two Upcoming Conferences

AmpliPhi Biosciences To Participate In Two Upcoming Conferences

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced...

AmpliPhi Biosciences Announces Publication Of Preclinical Data For AB-PA01 Showing Activity In Reducing Biofilms Of Pseudomonas Aeruginosa

AmpliPhi Biosciences Announces Publication Of Preclinical Data For AB-PA01 Showing Activity In Reducing Biofilms Of Pseudomonas Aeruginosa

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced the...

AmpliPhi Biosciences' CEO To Moderate Panel Discussion At Upcoming Anti-Infectives Rx Conference

AmpliPhi Biosciences' CEO To Moderate Panel Discussion At Upcoming Anti-Infectives Rx Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that CEO...

AmpliPhi Biosciences Announces First Intravenous Treatment Of A Patient With AB-SA01 Targeting Staphylococcus Aureus

AmpliPhi Biosciences Announces First Intravenous Treatment Of A Patient With AB-SA01 Targeting Staphylococcus Aureus

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the...

AmpliPhi Biosciences Announces Receipt Of $2.0 Million R&D Tax Incentive

AmpliPhi Biosciences Announces Receipt Of $2.0 Million R&D Tax Incentive

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it...

AmpliPhi Biosciences To Present At Rodman & Renshaw 19th Annual Global Investment Conference

AmpliPhi Biosciences To Present At Rodman & Renshaw 19th Annual Global Investment Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that Paul...

AmpliPhi Biosciences Announces Publication Of Bacteriophage Case Study For Life-Threatening Antibiotic-Resistant Infection

AmpliPhi Biosciences Announces Publication Of Bacteriophage Case Study For Life-Threatening Antibiotic-Resistant Infection

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces publication of...

AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the three and six months ended...

AmpliPhi Biosciences To Hold 2017 Second Quarter And Business Update Conference Call On August 14

AmpliPhi Biosciences To Hold 2017 Second Quarter And Business Update Conference Call On August 14

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business...

AmpliPhi Biosciences To Present At Bacteriophage Therapy Workshop Sponsored By The FDA And NIH

AmpliPhi Biosciences To Present At Bacteriophage Therapy Workshop Sponsored By The FDA And NIH

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that it has been invited to...

AmpliPhi Biosciences Announces Presentation And Panel Participation At BIO International Convention

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO Dr.

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. As Chief Executive Officer

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C.

AmpliPhi Biosciences To Present At 7th Annual LD Micro Invitational Conference On June 6

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO M.

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results And Provides Business Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31,...

AmpliPhi Biosciences To Hold Business Update Conference Call On May 15

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update...

AmpliPhi Biosciences Announces Closing Of Public Offering

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its...

AmpliPhi Biosciences Announces Pricing Of $10.4 Million Underwritten Public Offering Of Common Stock And Common Warrants

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an...

AmpliPhi Biosciences Announces A New Strategic Emphasis On Personalized Therapies For Serious Or Life-Threatening Antibiotic-Resistant Infections

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the field of bacteriophage technology, announces a new strategic emphasis on precisely targeted and personalized medicines designed to address the surging...

AmpliPhi Biosciences Announces Presentation Of Personalized Bacteriophage Therapy Case Study For Life-Threatening Antibiotic-Resistant Infection At Scientific Conference

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that a case study highlighting the...

AmpliPhi Biosciences Announces Positive Feedback From FDA On Phase 2 Development Proposal

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that the U.

AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that its board of directors has approved...

AmpliPhi Biosciences Announces Presentations Of Clinical And Preclinical Data From Studies With Its Bacteriophage Technology At Two Scientific Conferences

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that data from its investigational...

AmpliPhi Biosciences Reports 2016 Fourth-Quarter And Full-Year Results And Provides Corporate Highlights

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the quarter and...

AmpliPhi Biosciences To Present At The 29th Annual ROTH Investor Conference

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M.